APA Explores Biomarkers for Mental Health Diagnosis

The American Psychiatric Association (APA) is considering a major change in mental health diagnoses by incorporating biomarkers into future versions of its Diagnostic and Statistical Manual of Mental Disorders (DSM). The DSM serves as a critical guide for clinicians in assessing patients and for insurance companies in determining coverage.

Biomarkers are biological indicators of mental illness that could be identified through diagnostic tests. While not yet ready for widespread use, the APA's January 2026 paper outlined ideas for their integration. Jonathan Alpert, vice chair of the APA's Future DSM Strategic Committee, stated that adding biomarkers to the DSM would be "a very big deal."

The potential benefits of using biomarkers include streamlining insurance coverage decisions and assisting clinicians in making faster and more accurate diagnoses and treatment recommendations. This could move beyond the current "trial-and-error approach" often seen in prescribing psychiatric medications.

For instance, in depression, about a quarter of patients have elevated levels of C-reactive protein, an inflammatory protein detectable by a blood test. Research suggests these individuals may respond better to drugs altering dopamine levels rather than only selective serotonin reuptake inhibitors (SSRIs).

However, significant research is still needed to validate these metrics for patient care, and concerns exist regarding healthcare costs, insurance coverage, and patient privacy. The integration of biomarkers represents a potential major change in how mental health conditions are diagnosed and treated.